[The effect of cerebrocrast on erythrocyte function].
The new calcium antagonist cerebrocrast intravenously infused in a dose of 0.4 micrograms.kg-1.min-1 during 15 min prevented erythrocyte deformability disturbances at the end of cerebral ischemia in rats, which was induced by carotid artery occlusion during 30 min. The agents also prevented the deformability 1 hour after the onset of recirculation. Cerebrocrast reduced spontaneous erythrocyte aggregation, the strength of erythrocytic aggregates, and hemoglobin affinity for oxygen. The latter effect was associated with the drug-induced increase in erythrocytic 2,3-diphosphoglycerate levels.
Plotnikova
T M
TM
Firsov
N N
NN
Saratikov
A S
AS
D000818:Animals; D002121:Calcium Channel Blockers / Q000494:pharmacology* / Q000627:therapeutic use; D004095:Dihydropyridines / Q000494:pharmacology* / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D004903:Erythrocyte Aggregation / Q000187:drug effects; D004907:Erythrocyte Deformability / Q000187:drug effects; D004912:Erythrocytes / Q000187:drug effects* / Q000502:physiology; D006863:Hydrogen-Ion Concentration; D002546:Ischemic Attack, Transient / Q000097:blood / Q000188:drug therapy; D008297:Male; D010108:Oxyhemoglobins / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D013997:Time Factors
D002121:Calcium Channel Blockers; D004095:Dihydropyridines; D010108:Oxyhemoglobins; C073838:2,6-dimethyl-3,5-bis(2'-propoxyethoxycarbonyl)-4-(2''-difluoromethoxyphenyl)-1,4-dihydropyridine
Vliianie tserebrokrasta na funktsional'noe sostoianie éritrotsitov.